title: Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer.
authors.forename: O
authors.initials: O
authors.lastname: Bilgi
authors.forename: B
authors.initials: B
authors.lastname: Karagoz
authors.forename: A
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: A
authors.initials: A
authors.lastname: Ozgun
authors.forename: T
authors.initials: T
authors.lastname: Tuncel
authors.forename: E
authors.initials: E
authors.lastname: Gokhan-Kandemir
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D000077146:Irinotecan; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D002166:Camptothecin